α1-抗胰蛋白酶Z等位基因与普通人群静脉血栓栓塞风险
每增加一个Z等位基因风险比为1.2(1.0-1.3),UK Biobank验证比值比为1.2(1.1-1.3)。ZZ纯合子绝对风险为7.8%(3.6-12.1),归因分数为0.7%(0.1-1.3)。
要点
- α1-抗胰蛋白酶ZZ纯合子与静脉血栓栓塞风险增加2.2倍相关。
- 每增加一个Z等位基因,静脉血栓栓塞风险比为1.2。
- Z等位基因人群归因分数与凝血酶原G20210A相当,低于因子V Leiden。
核心结论
- α1-抗胰蛋白酶ZZ纯合子与静脉血栓栓塞风险增加2.2倍相关,其人群归因分数与凝血酶原G20210A相当。
主要发现
- 随访期间非携带者诊断静脉血栓栓塞6649次,杂合子436次,纯合子10次。
- 杂合子和纯合子相对于非携带者的风险比分别为1.1(95%CI 1.0-1.2)和2.2(1.3-3.7)。
- 每增加一个Z等位基因风险比为1.2(1.0-1.3),UK Biobank相应比值比为1.2(1.1-1.3)。
- ZZ纯合子绝对风险为7.8%(3.6-12.1),凝血酶原G20210A为20.1%(9.1-31.2),因子V Leiden为15.0%(12.6-17.4)。
- Z等位基因归因分数为0.7%(0.1-1.3),凝血酶原G20210A为1.2%(0.9-1.6),因子V Leiden为10.5%(9.9-11.1)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The α1 -antitrypsin Z (rs28929474) allele may lead to alterations in hemostasis either through liver disease or effects on coagulation factors. OBJECTIVES: To test the hypothesis that the α1 -antitrypsin Z genetic variant is associated with increased risk of venous thromboembolism. METHODS: A total of 107 075 individuals from the Copenhagen General Population Study were used to test the association of the α1 -antitrypsin Z genetic variant with risk of venous thromboembolism, including deep venous thrombosis and pulmonary embolism, prospectively. Confirmatory analyses were done in the UK Biobank. RESULTS: During follow-up, venous thromboembolism was diagnosed 6649 times in noncarriers, 436 times in heterozygotes, and 10 times in homozygotes. Hazard ratios for venous thromboembolism in α1 -antitrypsin Z heterozygotes and homozygotes versus noncarriers were 1.1 (95% confidence interval, 1.0-1.2) and 2.2 (1.3-3.7). A one Z allele increase was associated with a hazard ratio for venous thromboembolism of 1.2 (1.0-1.3). The corresponding odds ratio in the UK Biobank was 1.2 (1.1-1.3). The absolute risk of venous thromboembolism associated with α1 -antitrypsin ZZ homozygosity was 7.8% (3.6-12.1). The corresponding estimates were 20.1% (9.1-31.2) for prothrombin G20210A and 15.0% (12.6-17.4) for factor V Leiden. The fraction of venous thromboembolic events attributable to the α1 -antitrypsin Z allele was 0.7% (0.1-1.3). For the prothrombin G20210A and factor V Leiden mutations, population attributable fractions were 1.2% (0.9-1.6) and 10.5% (9.9-11.1). CONCLUSION: In conclusion, α1 -antitrypsin ZZ homozygosity was associated with a 2.2-fold risk of venous thromboembolism and had a comparable population attributable fraction to prothrombin G20210A.
引用
- Riis J, Nordestgaard BG, Afzal S, et al. α1 -Antitrypsin Z allele and risk of venous thromboembolism in the general population. J Thromb Haemost. 2021. PMID: 34662507. doi:10.1111/jth.15556
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。